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Technology advances in rapid diagnosis and clinical monitoring of human immunodeﬁciency virus (HIV) infection have been
madeinrecent years, greatlybeneﬁting thoseatriskofHIVinfection,thoseneeding careandtreatment, andthoseonantiretroviral
(ART) therapy in sub-Saharan Africa. However, resource-limited, geographically remote, and harsh climate regions lack uniform
access to these technologies. HIV rapid diagnostic tests (RDTs) and monitoring tools, such as those for CD4 counts, as well as
tests for coinfections, are being developed and have great promise in these settings to aid in patient care. Here we explore the
advances in point-of-care (POC) technology in the era where portable devices are bringing the laboratory to the patient. Quality
management approaches will be imperative for the successful implementation of POC testing in endemic settings to improve
patient care.
1.Introduction
Human immunodeﬁciency virus (HIV) testing has rapidly
expanded in endemic settings due primarily to an inﬂux of
funding from The Global Fund to Fight AIDS, Tuberculosis
and Malaria, The US President’s Emergency Plan for AIDS
Relief (PEPFAR), the World Bank, and other donors. The
most notable testing successes have been achieved in pre-
vention ofmother-to-child transmission (MTCT) programs,
voluntary counseling and testing (VCT) centers, sexually
transmitted disease (STD) clinics, and integrated programs
pertaining to comorbidities such as malaria and tuberculosis
(TB) [1]. Resource-limited settings (RLSs) oftentimes over-
lapwiththeHIVepidemicandsuch settings aresynonymous
with a lack of well-trained laboratory personnel, poor physi-
calinfrastructure, extreme climate,and geographic isolation;
all of which impact the use of laboratory technologies where
they are needed most.
2.QualityManagement
Selection of point-of-care devices for HIV-endemic settings
requires a quality management (QM) approach. Quality
control (QC; operational approaches to ensure functional
quality requirements) and quality assurance (QA; systematic
approaches to ensure conﬁdence in performance) both play
a role in POC evaluation compared to a “gold standard”
and implementation in the patient population. Speciﬁcally,
performance characteristics such as the sensitivity (the
percentage of results that are correctly identiﬁed as positive),
speciﬁcity (the percentage of results that are correctly iden-
tiﬁed as negative), and robustness (performance in presence
of operator, environmental conditions) should be evaluated
before tests are deployed.
The sheer volume of various testing associated with HIV
conducted in sub-Saharan Africa does not provide much
room for testing error. A mere 0.5% error rate in 10 million2 Journal of Tropical Medicine
tests could result in 50,000 patients misdiagnosed or mis-
managed in clinical care. This error rate could lead to more
transmitted infections to the unborn and sexual partners of
this tested population, and could be detrimental to those
requiring immediate ART. When considering a POC device
for implementation in a given endemic population, it is
important to validate the technique compared to a “gold
standard” alternative method, speciﬁcally VL, Western blot
(WB), or ELISA/EIA for HIV diagnosis, and ﬂuorescence-
activated cell sorting (FACS) for CD4 monitoring. Westgard
standards [2] suggest a minimum of 40 high-quality speci-
mens from the patient population to be compared between
the POC method being evaluated and the “gold standard”
laboratory technology. Larger numbers of specimens (100–
200) are recommended to assess whether the new method’s
speciﬁcity is similar to that of the established comparator
method. Specimens should be selected to cover the entire
clinically signiﬁcant range, as well as working range of
the two methods. Bland-Altman models serve as a good
measureofcorrelationbetweentwomethodsbeingevaluated
[2]. According to College of American Pathologists (CAP)
and Clinical and Laboratory Standards Institute (CLSI)
guidelines, POC technology should be compared at least
twice annually to the laboratory comparator for continued
performance evaluation.
3.HIV Testing
HIV technologies for diagnosis have included direct detec-
tionapproachesbasedonspeciﬁcviralantigenquantiﬁcation
such as the p24 antigen [3] and qualitative nucleic acid
ampliﬁcation tests (NATs) such as polymerase chain reaction
(RT-PCR) ampliﬁcation [4–6], and indirect or antibody-
based tests such as Western blots, direct or indirect ELISA
or EIA formulated into POC rapid diagnostic tests (RDTs)
are widely available [7, 8]. The rapid scale-up of POC
testing seen in recent times is largely attributed to successful
concepts such as portable glucometers, urinalysis dipsticks,
and hemoglobin spectrophotometers (e.g., HemoCue), but
particularly for HIV screening using RDT [7, 8]. The bulk of
these HIV RDTs are immunochromatographic tests (ICTs)
performed using blood or blood derivatives, and a handful
using urine [9, 10]a n do r a lﬂ u i d[ 11, 12], with lateral
capillary ﬂow and quality controls incorporated into the test
kit. A major shortcoming of these technologies has been
poor-to-modest speciﬁcity which has promoted the use of
combined RDT or combined alternative testing methods for
screening and testing programs, particularly when conﬁrm-
ing a positive diagnosis. From an immunologic aspect, RDT
performance is aﬀe c t e db yt h ed i v e r s i t yo fc i r c u l a t i n gH I V
subtypes (regionally as well as within an individual), HIV-2,
as well as poorly understood immune cross-reactivity [13–
18]. However, improvements to kit storage conditions (no
need for cold-supply chain), quick turnaround time (<20
minutes), and the ease in performance make these POC
tests very attractive in RLS [13–16] .R D T sa r em o r ea ﬀord-
able than laboratory-based tests and require no laboratory
infrastructure tosupportscale-up.The importanceofproper
quality management in test evaluation, method validation,
and smart implementation, as well as coordinated training
requirements before use, cannot be overstressed for these
POC devices to be eﬀective.
Testing for HIV at the POC has changed the landscape of
surveillance in endemic settings. The low-cost, ﬂexible trans-
port and storage requirements, and the lack of a need for
well-trained laboratory technicians have greatly aided in
their successful implementation [13–16]. With the decen-
tralization of health care workers (HCWs) in RLS, mobility
transfers and staﬀ turn over issues, increasing visibility of
counselors coupled with less-trained individuals performing
RDT, adequate training, supervision and assessment will be
imperative for proper sample collection, analysis, and inter-
pretation. HCW will require initial clinician oversight, and
regular structuredfollow-up assessment, toensure thathigh-
quality specimens are being collected, credible testing per-
formed, and any training gaps correctly identiﬁed and timely
addressed. Clear SOPs illustrating the stepwise technique for
collection of specimens should be implemented at each site
(e.g., ﬁnger-stick blood versus whole blood or interstitial
ﬂuid). Reassessment of RDT procedures will ensure high-
qualitybloodspecimens are being collected,positive patient-
HCW interactions reinforced, and pain minimized. This will
be very important for pediatric populations and will aid in
increasing numbers tested and patient retention, if patients
have a favorable view of HIV testing and community HCW.
Currently, there are seven FDA-approved HIV RDT on
the market; however many more products are approved by
other regulatory agencies and are currently in use [13, 19,
20]. Due to high prevalence of HIV in certain settings, em-
ploying accurate HIV RDT is not only important in patient
care but also in program eﬃciency. As mentioned before,
with a high test volume, a mere 0.5% error rate among 10
million people screened would result in 50,000 patients mis-
diagnosed (false-positive or false-negative).
Performance evaluationofRDTis oftentimes overlooked
before implementation in endemic settings. The CDC and
WHO have made great strides in supporting performance
evaluationof HIV RDT in speciﬁc regions, so that Ministries
of Health can roll out approved products [19, 21]. The per-
formance characteristics of RDT in HIV-endemic settings,
unfortunately, are less straightforward than what appears
true with CD4 tools. Diverse HIV-1 and HIV-2 subtypes
circulating regionally, as well as within patient recombinant
and dual infections, all aﬀect the performance of HIV RDT
[13, 14]. Most HIV RDTs are based on antigens from HIV-1
subtype B, thus it is important to evaluate their performance
based on the coating antigen and with respect to circulating
subtypes [13]. One study evaluating OraQuick HIV-1/2
(OraSure Technologies, Inc., Bethlehem, PA) RDT on stored
specimens from a blood bank in Kinshasa, Democratic Re-
public of Congo (DRC), reported 100% speciﬁcity and
sensitivity among 72 known HIV-positive, non-subtype-B-
conﬁrmed specimens [22]. It will be important in the future
for such controlled performance evaluations to ensue else-
where in sub-Saharan African settings.
Studies have shown that poor performance is still en-
counteredusing approvedRDTtesting algorithms. Poor sen-
sitivity and speciﬁcity has been demonstrated in controlledJournal of Tropical Medicine 3
performance evaluations in Uganda [15, 16], the DRC [17],
Ethiopia [23], and Cameroon [24]. In Uganda and the DRC,
performance evaluations have demonstrated weak-positive
bands with some RDTs, notably the Determine HIV 1/2
RDT (Determine; Abbott Laboratories, Germany) [15–17].
In Uganda, when weak-positive bands were included in
performance evaluation, as per manufacturer’s instructions,
the test had low speciﬁcity (94.1%) and a low PPV (74.0%).
Exclusion of the 37 samples (5.8%) with a weak-positive
band improved the speciﬁcity (99.6%) and positive predic-
tive value (97.7%) compared to EIA and Western blot (WB).
In the DRC study [17], a high number of false-positive
results, due to inclusion of weak-positive bands, was discov-
ered when compared to WB and p24 EIA (Immunocomb
Conbﬁrm HIV-1/2-antibody, Orgenics, Yavne, Israel).
In a subsequent evaluation in the same Ugandan pop-
ulation [16], Determine was reevaluated, as were four new
commercially available RDTs: Uni-Gold HIV (1/2) (Uni-
Gold; Trinity Biotech, Ireland); STAT-PAK HIV 1/2 (STAT-
PAK; Chembio Diagnostic Systems Inc., USA); Advanced
Quality Rapid Anti-HIV 1/2 (Advanced Quality; IncTec
Product Inc., China); First Response 1-2.0 (First Response;
PMC Medical, India). All tests demonstrated a sensitivity of
100% however Determine had low speciﬁcity [85.2%, PPV
67.3% (Exact Clopper-Pearson 95% CI: 52.9, 79.7)], as did
Uni-Gold and First Response [97.4%, PPV 92.1% (Exact
Clopper-Pearson95% CI:78.6,98.3)].STAT-PAK performed
well [speciﬁcity 99.1%, PPV 97.2% (Exact Clopper-Pearson
95% CI: 85.5, 99.9)], and Advanced Quality had sensitivity,
speciﬁcity, and PPV of 100% (Exact Clopper-Pearson 95%
CI: 90.0, 100.0). Including the indeterminate samples in
one Cameroonian study reduced the speciﬁcity of all RDTs
evaluated in this setting [24]. Genie II HIV-1/HIV-2 (Bio-
Rad, Marnes-la-Coquette, France) speciﬁcity was 98.2%,
and the speciﬁcities of Camstix (Camdiagnostix, Yaounde,
Cameroon), Determine, and Enzygnost HIV Integral (Dade-
Behring, Pennsburg, Germany) were 88.3%, 90.6%, and
92.3%, respectively. When evaluating Determine and ELISA
in Ethiopia [23], these data showed 94.4% concordance in
HIV antibody testing among blood donors. The sensitivity,
speciﬁcity, positive and negative predictive values of Deter-
mine were 60.5%, 98.9%, 88.5%, and 94.9%, respectively.
Oral ﬂuid sampling for HIV RDT could prove partic-
ularly useful in RLS since there would be no blood sam-
ple requirement, particularly beneﬁting the uptake among
children. A handful of these tests have been evaluated in
HIV-endemic settings. OraQuick ADVANCE Rapid HIV-
1/2 (OraSure Technologies) was evaluated among 591 rural
youthattendingaVCTcenterinZimbabwe.Whencompared
to dry-blood spot preparations evaluated by an ELISA
(Vironostika, Biomerieux BV, Boxtel, The Netherlands) and
WB (MP Diagnostics, St. Ingbert, Germany) algorithm,
OraQuicksensitivityandspeciﬁcitywereanimpressive100%
[11]. In Namibia, OraQuick and OraSure Rapid HIV-1/2
(OraSure Technologies) RDTs were evaluated among preg-
nant women, who provided oral ﬂuid samples and paired
blood samples for dual ELISA comparison [AxSYM HIV
1/2 gO (Abbott, Abbott Park, IL); Access HIV 1/2 New test
(Bio-Rad Laboratories)]. OraQuick results for 273 women
revealed 100% speciﬁcity and sensitivity, whereas OraSure
results from the same women yielded 97.1% sensitivity
and 99.5% speciﬁcity. Concordance between OraQuick and
OraSure results was high ([kappa] = 0.97; 95% CI: 0.95–
0.99) [12]. Continued performance evaluations of oral ﬂuid
specimens for RDT are greatly needed, particularly in young
infants and children, pregnant and lactating mothers, as well
as in various HIV-subtype settings to account for potential
immunologic variation.
Fourth-generation HIV RDTs are being developed and
warrant extensive performance evaluation in the ﬁeld. One
such test, ARCHITECT HIV Ag/Ab Combo Assay (Abbott
Laboratories), was FDA-approved in 2010 as the ﬁrst RDT
that detects antigen and antibodies for HIV simultaneously
[20]. In addition, it has been indicated for use in pregnant
women and children ≥2 years of age and in diagnosing
acute HIV-1 infection. The test incorporates the HIV-1 p24
a n t i g e na sw e l la sa n t i b o d i e st oH I V - 1g r o u p sMa n dO ,
as well as antibodies to HIV-2. The Determine HIV 1/2
Ag/Ab Combo (Inverness BioMedical, Waltham, MA) was
recently evaluated by the CDC/USAID and provided HIV
antigendetectionabout10days(mean time)beforeantibody
detection when using seroconversion panels in a controlled
laboratory setting [13]; however this promising RDT will
need to be evaluated in diverse ﬁeld settings and in areas
of various circulating subtypes and background pathologies.
The potential beneﬁt of including such an RDT in HIV
screening programs couldbe useful indetecting recent infec-
tions, prior to the emergence of HIV antibodies, therefore
reducing the window period of antibody detection. The
median detection time was demonstrated to be 7 days earlier
(range 0 to 20 days) compared to 3rd-generation EIA tests to
which they were compared [20].
External quality assessment (EQA) programs for HIV
RDT are greatly needed in sub-Saharan Africa in order to
ensure selected tests areperforming accuratelyand according
to manufacturer’s expectations. The CAP provides member
laboratories proﬁciency testing (PT) panels for anti-HIV-
1/2 as well as HIV-1 p24 for peer comparison. Programs
modeled aftertheCAPPTprogramwill enableregional EQA
programs to improve the performance of selected tests and
improve testing accuracy.
In the aforemenioned studies in sub-Saharan Africa,
RDT sensitivities ranged from 94.1% to 100%, and speci-
ﬁcities ranged from 85.2% to 100% when performed and
interpreted according manufacturers’ instructions [9, 11, 12,
15–17, 23, 24]. HIV EQA programs, targeted speciﬁcally at
ICT RDT, will likely improve the performance of selected
tests and improve diagnostic accuracy overallin sub-Saharan
Africa. Misdiagnoses of HIV infection can cause improper
patient care and allow for progression to AIDS if not
identiﬁed early, thus these studies suggest a three-part QM
approach to implementing HIV RDT. First, validation of a
RDT in a speciﬁc population must be conducted in compar-
ison to known local HIV-positive and HIV-negative panels
with conﬁrmatory testing by WB or EIA. It is possible that
HIV-subtype immune responses may aﬀect the reactivity
on RDT [14–17, 23]. Secondly, there is a need to conﬁrm
indeterminate bands on RDT by alternative methods before4 Journal of Tropical Medicine
a result is determined and a diagnosis is assigned. Given the
socialandpsychologicalconsequencesofafalse-positiveHIV
diagnosis, as well as the probably poor clinical outcomes
and onward HIV transmissions among those given a false-
n e g a t i v er e s u l t ,c o n ﬁ r m a t o r yt e s t i n gi sn e e d e d .T oi n c r e a s e
accuracy of RDT, a multiple-test algorithm, speciﬁc to the
population, should be validated to account for subtype-
speciﬁc immune responses and nonspeciﬁc immune cross-
reactivity of antibodies. When implementing HIV RDT test-
ing algorithms involving multiple RDTs, countries need to
provideclearguidanceonhowtodealwithdiscordantresults
based on the speciﬁc ﬁndings of performance evaluations.
Fourth-generation tests potentially could shorten the
window period of a positive antibody result, thus detecting
infections earlier and preventing onward transmissions.
However, due to the relatively new arrival of these tests from
the regulatory pipeline, performance evaluations in various
RLSs, and among diverse patient populations (HIV sub-
type distribution, various ages, varying VL, pregnant) is
warranted before implementation. Nonbloodspecimen plat-
forms, such as those based on urine and oral ﬂuid, should
be evaluated to increase the uptake, particularly in remote
settings where turnaround times are long, and it may be
unfeasible to wait and return for ELISA/EIA results. POC
resultsdistributionatthetimeoftestingcouldprovideample
opportunityforriskreductioncounseling anddecreaselong-
term followup among these patients.
In sub-Saharan Africa, the cost of an HIV RDT ranges
from $1.23 to $4.00 per test [13]. The small kit size, light
weight, as well as minimal separate reagent components,
enable bulk shipment of these RDTs from distributors and
eventual onward transport by post or road vehicle to remote
sites.
4.HIV ClinicalMonitoring
In ﬁscal year 2010, nearly 33 million people were tested for
HIVsolely in PEPFAR countries, an enormous scale up from
previousyears [25]. With HIV testing at an all-time high and
new “test and treat” programs being explored [26], this will
result in millions more positive diagnoses and will require
clinical laboratory monitoring for those who are eligible
for antiretroviral therapy (ART). Clinicians are gradually
moving away from using clinical presentation and/or total
lymphocyte counts to determine ART eligibility; however,
manyARTprogramsinRLSstillrelyonimmunologicand/or
clinical presentation to measure response to therapy and to
determine when to change to a second-line regimen [27–
30]. The 2010 WHO/UNAIDS recommendations call for all
t h o s ew h oa r ed i a g n o s e dH I V - p o s i t i v et oh a v ea c c e s st oC D 4
counts and use an ART treatment cut-oﬀ of ≤350 CD4+
T-cells/µL for adults and adolescents [31]. The CDC has
established a treatment cut-oﬀ CD4+ T-cell percentage of
<25% forinfants under11 months of age, <20% for children
up to 3 years of age, and <15% for children between 3 and 5
years of age [32].
CD4 counts are primarily determined by FACS on ﬂow
cytometers which are costly, require a cold chain, need rou-
tine technical maintenance, require skilled technicians, and
are primarily located in urban centers. When considered
alone, CD4 data have been shown to misclassify patients as
immunologic ART failures in Malawi (30% misclassiﬁed)
[27], Uganda (20.2% misclassiﬁed) [29], and South Africa
(18.5% misclassiﬁed) [28]. Relying solely on clinical presen-
tation for ART initiation can result in poor patient care and
can lead to AIDS progression or death. Clinical presentation
had a low sensitivity of 15.2% in determining ART eligibility
in South Africa [28] and resulted in 57% of patients being
misclassiﬁed in Malawi [27]. Italso has correlated with death
within 30 months among 41.3% of patients followed in
Uganda [29].
Eﬀorts are underway to bring the clinical laboratory to
the patient for clinical care. POC devices for CD4 immuno-
logic monitoring [33–35] and toxicity monitoring (e.g.,
lactate, renal function tests [RFT],liver function tests [LFT])
[36, 37] are currently being evaluated or in the development
pipeline. These tools have the potential to change the land-
scape of clinical care among HIV-infected patients in RLS,
but only packaged with proper training and good quality
management programs will we be able to realize their utility.
Clinical monitoring of HIV disease by CD4 enumeration
would greatly be enhanced with POC devices. If validated,
these devices could rapidly and accurately identify CD4
counts with minimal operator training, infrastructural setup
and withless costthanstandard laboratory-based equipment
such as ﬂow cytometers. These machines have a quick turna-
round time per test (5–30 minutes), are fully automated
with minimal sample volume, minimal preanalytical sample
processing, and no cold chain requirements. Additionally,
ﬂexible power supply options to allow usage in RLS, com-
bined reagents, and minimal supplies, simplify supply-chain
management. They are also usually enabled to provide in-
stant paper results for attachment to patients documents
as well as inbuilt data storage units. The beneﬁt of POC
machines in patient care lies greatly in shortening the deci-
sion time pending results from conventional machines, re-
sulting in real-time treatment decisions, since patients
routinely walk or commute for great distances to reach ART
treatment programs in RLS.
It is important to note that CD4 indices are crucial for
monitoring pre-ART disease progression but may perform
suboptimally in identifying treatment failure as compared
to VL quantiﬁcation [27–30] but given the expense and
logistical issues associated with NAT platforms, CD4 eval-
uation even on ART treatment provides a fairly reasonable
monitoring option in RLS. One promising POC monitoring
device is the PIMA analyzer (Alere, Inc., Waltham, MA)
which enumerates CD4 counts in 20min from a ﬁnger-stick
blood sample or blood in EDTA. The PIMA has been eval-
uated in South Africa and in Zimbabwe and performs well
compared to goldstandard FACS analysis. In a SouthAfrican
mobile VCT clinic setting [35], the PIMA was evaluated on
venous and ﬁnger-stick blood across three diﬀerent PIMA
devices in parallel, and with four diﬀerent technicians.
Performance was adequate compared to EPICS XL-MCL
cytometry (Beckman Coulter) on venous blood [R2 = 0.92,
mean diﬀerence (Bland Altman) = –12cells/µL, (95% CI –23
to –1), 94% sensitivity, 98% speciﬁcity, 84% PPV]. UsingJournal of Tropical Medicine 5
ﬁnger-stick blood,the PIMAalso performed well [R2 = 0.92,
mean diﬀerence = 15 cells/µL, (95% CI –9 to 39), 100%
sensitivity, 98% speciﬁcity, 67% PPV]. In Zimbabwe, ﬁnger-
stick blood with a PIMA performed well when compared to
venous blood on a FACSCalibur (Becton Dickinson) [mean
absolute CD4 diﬀerence = +7.6 cells/µL, P = 0.72] [33]. In
the same study, PIMA and FACSCalibur analyses conducted
by both nurses [mean absolute CD4 = +18.0 cells/µL,
P = 0.49] and laboratory technicians [mean absolute CD4 =
−3.1 cells/µL, P = 0.93] indicated adequate performance
which provides access to larger manpower in RLS.
Becton Dickinson is developing an easy-to-use, image-
based counting technology suitable for RLS that will provide
CD4 absolute count, CD4%, and hemoglobin, all on the
same single-use disposable cartridge. Features of the auto-
mated devicewill includetouch screenuserinterface, ﬂexible
workﬂow with high throughput, an integrated microprinter,
batteryorsolar-powered capability,and dataarchive/transfer
capabilities. The sample is collected from the patient using a
ﬁnger-stick or from an EDTA tube. After a short incubation
period the cartridge is read quickly requiring only a single
step. The new and innovative cartridge technology contains
dried reagents with no cold chain requirements, which
enables longer shelf life over a wide range of environmental
conditions (Becton Dickinson, Mikulski L., personal com-
munication, 2011).
It will be important for continued performance evalu-
ations of PIMA and other devices, with consideration for
robustness measures, such as evaluation in remote setting
that are hot and either humid or dry, among large numbers
of young infants and children with ﬁnger-prick sampling, as
well as over a broad range of CD4 counts in HIV-positive
patients. Performance evaluation among lay counselors,
such as in VCT centers, should be also be pursued. Also
important to consider will be the cost of such instruments
and associated consumables as many ART programs have
ﬁnancial constraints due to the sheer number of patients in
their care.
When implementing POC tests for CD4 enumeration,
EQA is an important aspect of the total QMS. EQA bodies
such as the United Kingdon Natioanl Quality Assessment
Service (UKNEQAS) and CAP implement programs for
member laboratories which perform CD4 enumerations.
Proﬁciency testing panels are distributed six times per
annum for UKNEQAS and three times per annum for CAP,
and member laboratories are graded on their accuracy com-
pared to known specimens.
HIV-positive patientsonART,particularly stavudinereg-
imens, are at risk for systemic toxicity,includinglactic acido-
sis,renaland/orkidneyfunctionimpairment,andevendeath
[32, 36, 37]. Clinical chemistry laboratory service is often-
times limited to hospitals and ART centers in urban areas, is
of questionable quality, and can have long turnaround times
for results delivery. Several POC devices have been evaluated
in sub-Saharan Africa and elsewhere for performance and
utility. At two clinics in Uganda, the Accutrend Lactate ana-
lyzer (Accutrend, Roche Diagnostics, Mannheim, Germany)
wasaccurate,reliable,andcosteﬀective[35–37].Inonestudy
[36], there was good correlation comparing Accutrend to
the Cobas Integra 400 plus (Roche) hospital standard meth-
od [R2 = 0.94, bias = −0.06], demonstrating superb agree-
ment between the POC instrument and the laboratory
method. In another Ugandan study [37], the Accutrend
determined lactate of ≥4.0mmol/L was 88.3% sensitive and
71.2% speciﬁc at determining in-hospital mortality among
a predominantly HIV-infected severe sepsis cohort. Overall,
a 7-fold increase in mortality was determined at a cut-oﬀ
lactate measurement of 4.0mmol/L indicating that accurate,
reliable testing is imperative for proper patient care in this
population.
In a recent study in Mozambique [34], nurses performed
POC clinical chemistry with the Reﬂotron Plus (Roche) for
alanine aminotransferase (ALT) and aspartate aminotrans-
ferase (AST) on ﬁnger-stick blood. Tests for ALT on the
Reﬂotron device had a mean bias of −0.2 U/l (LOA −10.5 to
10.0) whereas AST testing had a bias of −4.0 U/l(LOA −44.5
to 36.5). These results were similar to those observed when
the POC testing was performed by laboratory technicians,
resulting in a bias of −4.8 U/l (LOA −35.6 to 25.9) for ALT
and −6.4 U/l (LOA −29.8 to 17.0) for AST.
5.Diagnosing Comorbidities
In many settings, there is a need for RDT to diagnose co-
morbidities such as malaria and TB to guide clinical care
in HIV-endemic areas [38–42]. In sub-Saharan Africa, pre-
sumptive treatment of fevers with malaria drugs is extremely
common, and laboratory-conﬁrmed malaria diagnoses are
not uniformly conducted. As with any ICT RDT, test kits
should be stored and transported according to properly
listed conditions in the package insert, should be performed
according to manufacturer’s SOP for individual assays in a
well-lit setting, and should be read for interpretation by per-
sonnel trained on the speciﬁc test. Development of positive
control bands is used to judge validity with conﬁrmatory
testing either by “gold standard” smear microscopy or a
second RDT. If two sequential tests do not demonstrate
controlbands,testsshouldbeconsideredinvalid,andablood
smear read.
Very few studies have evaluated RDT for malaria diag-
nosis in HIV-positive populations. The Binax Now Malaria
RDT (Binax; Inverness Medical Innovations, Inc., Waltham,
MA) is an ICT based on the pan-Plasmodium antigen,
histidine-rich protein-2 (HRP-2) and has been evaluated in
ruralmobileclinicsinUgandabycliniciansevaluatingfebrile
adult HIV patients [38]. Compared to laboratory-conﬁrmed
thick blood smears, Binax sensitivity was 85.7% (95% CI:
57.2–98.2) and speciﬁcity was 97.8% (95% CI: 94.9–99.3)
indicating favorable, although imperfect performance, for
excluding malaria as the cause of fevers among HIV-positive
febrile patients. In another study in the same Ugandan
population[39],Binaxdemonstrateda malaria prevalenceof
31.1%amongscreenedmothers,butnosigniﬁcantdiﬀerence
was observed between HIV-positive mothers compared with
HIV-negative mothers (30.3% versus 32.3%, P = 0.72).
Vertical HIVtransmission was signiﬁcantly higherif mothers
had a positive Binax test (RR = 3.2, 95% CI: 1.14 to 9.2). The
highest rates of MTCT were among mothers who had both6 Journal of Tropical Medicine
placental malaria infection and Binax-diagnosed malaria
(30.4%), indicating the importance of using malaria RDT,
particularly in PMTCT programs [39].
Increasing TB drug resistance, coupled with a growing
number of patients coinfected with TB and HIV, has
highlighted the urgent need for more accurate and RDT,
with a POC device being an ultimate goal. Many patients in
sub-Saharan Africa have limited access to laboratory testing
which contributes to high rates of death during co-infection.
The Foundation for Innovative and Novel Diagnostics
(FIND, Geneva, Switzerland) is working with industry and
regulatory partners, to develop and validate RDT products
in TB, as well as in other disease areas. FIND has determined
that a successful POC test will consist of one which is used
wherepatientsseekmedicalcare,sincemanytimes,diagnosis
and treatment are based on clinical symptoms [41]. Current
platforms being evaluated include urinary antigen detection
and antibody detection at the POC.
The pan-mycobacterial antigen lipoarabinomannan
(LAM) has been identiﬁed as a promising candidate to in-
corporate into a POC test because of itstemperature stability
and detection in urine [42]. With hopes to build upon
commercially available ELISA platforms for the creation of
lateral ﬂow platform RDT, two studies [20, 43] have been
conducted to detect LAM in urine specimens with ELISA. In
Zimbabwe [43], the LAM ELISA sensitivity was 44% (95%
CI 36–52) for culture-conﬁrmed TB (52% in smear-positive
patients)andspeciﬁcitywas89%(95%CI81–94).Sensitivity
was signiﬁcantly higher in HIV- and TB- coinfected patients
(52%, 95% CI 43–62, P<0.001) compared to HIV-negative
TB patients (21%, 95% CI 9–37). Sensitivity in smear-
negative patients was very low (28%, 95% CI 13–43) for
combined HIV-positive and HIV-negative patients. In a
Tanzanian study [42], of all patients which had a positive
sputum culture, LAM ELISA was 80.3% sensitive. Sensitivity
of acid-fast bacilli sputum microscopy was 62.1%. TB
was diagnosed in 195 (49%), including 161 culture-positive
patientsandexcludedin114(29%)participants. LAMELISA
sensitivity was 44% (95% CI 36–52) for culture-conﬁrmed
TB (52% in smear-positive patients) and speciﬁcity was 89%
(95% CI 81–94).
Despite these imperfect study results, the search for a
sensitiveplatformtodetectTBantigenorantibody responses
continues. FIND has partnered with Antigen Discovery Inc.
and the Public Health Research Institute (USA) to dissect
theMycobacteriumtuberculosisproteome,inasearch towards
identifying a panel of diagnostically relevant antigens for
TB serology [40, 43] .T h eT Bp r o t e o m ea r r a y sa r eb e i n g
screened with TB patient sera and controls from across the
globe. Patient cohorts include those with and without HIV
infection and those with latent tuberculosis. FIND reports
that a limited number of combined antigen targets may be
translated into an RDT for active TB detection. Numerous
technological platforms appropriate for a broad range of
analyses have been evaluated, and a ﬁrst prototype assay is
expected in 2011 [40]. It will be important for such assays to
be evaluated across robust conditions with consideration for
test operators, climate, immune status, varied TB pathologic
states, and co-infections.
6.Conclusion
In order to achieve the ambitious goals of “test and treat”
program implementation and to promote universal access of
HIV-positive patients to ART in RLS, we must decentralize
laboratory technology for screening and clinical monitoring.
POC devices have proven to be easy to transport, operate,
and maintain in RLS[7–9, 11,44].Additionally,lowerskilled
staﬀ, such as lay counselors and nurses, are equally able to
perform these POC tests compared to trained laboratory
technicians [8, 9, 12, 14, 16, 36, 38]. Access to this additional
humanresource willprovide agreat advantage toavailtesting
and monitoring in the ﬁeld, where typically, health care staﬀ
are less trained and less technically savvy.
Another key to the successful implementation of POC
devices will be cost. Current laboratory-based testing and
monitoring technologies may be too expensive for most
programs in RLS, particularly for ART programs. In sub-
Saharan Africa, central laboratories come potentially with a
greater expense due to human resource and infrastructural
requirements. Only when combined with good QM systems
to ensure accuracy will these POC devices really transform
the availability of tests in real time to inform proper patient
care.
Numerous HIV RDTs are available, and many are being
evaluated in RLS with support from the US CDC and others
[13, 14, 16, 18, 19, 21]. HIV RDTs have great potential
when evaluated in strategic QM performance evaluations,
spanning various VL concentrations, HIV disease states and
when considering circulating subtypes. Consistent EQA and
retraining, particularly of lay persons, will be needed to
sustain their accuracy and availability in RLS. It is of utmost
importance that personnel are trained in proper sample
collection, with clear SOPs for various collection procedures
and biospecimen types to ensure a quality specimen. The
PIMA POC CD4 instrument is currently available in sub-
Saharan Africa and has handful of promising studies validat-
ing its use in RLS among HIV-positive patients to monitor
ART response [34, 35]. A POC VL device is greatly needed
to contribute to clinical decision making, particularly in
regions which are far remote and where ﬁnancial burden
prohibits routine VL to monitor ART. To accompany HIV
RDT, malaria and TB RDTs have the potential to add to the
diagnostic capacity in RLS and improve patient care in areas
of overlapping endemicity [38, 39, 41, 42]. Collaborative
eﬀorts have the capacity to combine technical expertise,
regulatory capacity as well as implementation expertise for
speeding up the development pipeline of products, perfor-
mance evaluation, and implementation at the country and
community level [13, 18, 19, 40].
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